NVS - Novartis AG
| Previous Close | 88.40 |
| Open | 87.17 |
| Bid | 83.77 x 800 |
| Ask | 88.66 x 1000 |
| Day's Range | 87.10 - 87.91 |
| 52 Week Range | 72.30 - 94.19 |
| Volume | 2,462,512 |
| Avg. Volume | 2,735,530 |
| Market Cap | 203.357B |
| Beta (3Y Monthly) | 0.84 |
| PE Ratio (TTM) | 15.31 |
| EPS (TTM) | 5.71 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.98 (3.42%) |
| Ex-Dividend Date | 2018-03-06 |
| 1y Target Est | 98.50 |
Zacks•2 days agoShould You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
- Zacks•2 days ago
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
- ACCESSWIRE•2 days ago
Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Novartis
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
- Zacks•3 days ago
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
- Benzinga•3 days ago
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
- Reuters•3 days ago
J&J says its psoriasis drug superior to Novartis treatment in study
Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study. After 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis's Cosentyx, J&J said.
- Zacks•4 days ago
Teva (TEVA) Stock Poised to Record Big Gains in 2019?
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.
- Benzinga•5 days ago
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...
- Insider Monkey•5 days ago
Here is What Hedge Funds Think About Novartis AG (NVS)
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
- Zacks•6 days ago
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
Amgen (AMGN) hikes its quarterly dividend by 10%.
- MarketWatch•9 days ago
Generic drugmaker Sandoz to sell alternative to EpiPen injectors
Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year.
- Reuters•9 days ago
Novartis to launch Adamis' EpiPen rival in U.S. next year
Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products. Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.
- Zacks•9 days ago
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
- Zacks•9 days ago
Roche's Kadcyla Halves Death Risk in Breast Cancer Study
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
- Zacks•11 days ago
Roche's Tecentriq Combination Gets Priority Review by FDA
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
- Zacks•11 days ago
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
- Zacks•11 days ago
Gilead (GILD) Announces Data on CAR T Therapy Candidate
Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
- Zacks•12 days ago
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
Market Realist•12 days agoAjovy Is a New Growth Driver for Teva Pharmaceutical
How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.
- Zacks•12 days ago
Global Blood Therapeutics' Voxelotor on Faster Approval Path
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
- Zacks•12 days ago
Glaxo to Sell India's Popular Horlicks Brand to Unilever
Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.
- Reuters•12 days ago
Novartis's new treatment for hives outperforms Xolair in trials
Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives. Xolair is sold by both Novartis and Roche, but has lost patent protection in Europe and the United States, leaving it exposed to rivals who are developing copies of the biological drug. Novartis said it now plans two Phase III studies for ligelizumab with more than 2,000 patients who suffer from chronic spontaneous urticaria (CSU), an autoimmune disease that causes persistent itchy reddish welts on the skin.
- Reuters•13 days ago
UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. The question of how long patients will benefit from Yescarta and other therapies in an expensive new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, has been a key topic at the annual meeting of the American Society of Hematology (ASH) in San Diego. Both Yescarta and rival Kymriah from Novartis AG have U.S. prices for lymphoma of $373,000 for health insurers including the Medicare government program for seniors.
